# Assessment of Nasal Deposition and Clearance of Ketorolac Solution Administered Using the Valois Nasal Spray Device

> **NCT01356212** · PHASE1 · COMPLETED · sponsor: **Egalet Ltd** · enrollment: 13 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Ketorolac tromethamine
- **DRUG:** Ketorolac tromethamine
- **DRUG:** Ketorolac tromethamine

## Key facts

- **NCT ID:** NCT01356212
- **Lead sponsor:** Egalet Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2002-10
- **Final completion:** 2002-12
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2017-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01356212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01356212, "Assessment of Nasal Deposition and Clearance of Ketorolac Solution Administered Using the Valois Nasal Spray Device". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01356212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*